• Bend Research has developed osmotic-delivery dosage forms that are effective for delivery of many active pharmaceutical ingredients, including those having high solubilities in aqueous solutions....

    Tech Brief
     
  • Bend Research has developed a inhalation drug-delivery platform based on engineered particles. This broadly applicable technology: delivers a high-fraction dose reproducibly, enables delivery of...

    Tech Brief
     
  • At Bend Research, we believe that time and money can be saved -- and the best drugs brought to market -- via rational implementation of delivery technologies and biological models early in the drug-...

    Tech Brief
     
  • Many therapeutically active molecules suffer from mechanism-based or off-target toxicities. An estimated 30% of clinical attrition is due to candidate toxicity or other safety issues, representing...

    Tech Brief
     
  • Bend Research's cGMP facility specializes in the production of advanced formulations for clinical trial materials. The facility is focused on versatility and quality, leveraging strong process...

    Tech Brief
     
  • Bend Research has two laboratories that provide cGMP analytical testing. The Quality Control laboratory, located at our cGMP manufacturing site, supplies timely support for all clinical manufacturing...

    Tech Brief
     
  • Bend Research develops/optimizes pharmaceutical engineering processes and technologies using an approach grounded in engineering fundamentals and creative experimentation to understand key physical...

    Tech Brief
     
  • An osmotic, oral, controlled-release capsule is described. This capsule provides drug delivery at fixed delivery rates (T80% = 6 or 14 h) independent of drug properties (e.g., solubility) or drug...

    Publication
     
  • Dextrans and derivatized dextrans are considered to have beneficial physical properties as potential carriers in engineered particle formulations. For water-soluble actives, e.g., albuterol sulfate,...

    Publication
     
  • This webinar discussed using amorphous dispersions as a platform technology to rapidly formulate compounds as respirable dry powders for preclinical evaluation. Dextran 10 was discussed as an...

    Webinar
     
  • Vodak D.T., D. Dobry, D. Lyon, P.J. Kuehl, E.G. Barrett, J.D. McDonald, and K. Rudolph, “Formulation Development and In Vivo Evaluation of a New Dry-Powder Formulation of Albuterol Sulphate in Beagle...

    Publication
     
  • Broadbent, A.L., R.J. Fell, S.L. Codd, K.A. Lightley, S. Konagurthu, D.G. Koehler-King, and J.D. Seymour, “Magnetic Resonance Imaging and Relaxometry to Study Water Transport Mechanisms in a...

    Publication
     

Pages